• The document is an intimation of a scheduled one-on-one meeting between Gland Pharma Limited and an institutional investor.
  • The event is a One-on-One Meeting with Abu Dhabi Investment Authority (ADIA).
  • The meeting is scheduled for November 20, 2026. A specific time and time zone were not disclosed in the announcement.
  • The stated purpose of the event is for an Analyst/Institutional Investor Meeting, as per the regulatory requirement.
  • The disclosure does not specify if the meeting is scheduled before or after an earnings announcement.
  • Management participants and their designations for the meeting were not provided in this intimation.
  • The announcement does not indicate that any presentation, earnings deck, transcript, or recording will be made available.
  • The document does not contain a specific compliance statement indicating that no unpublished price sensitive information (UPSI) will be shared.

Additional Notes Section

  • This is a standalone regulatory filing and does not list any attachments such as invites, investor decks, or compliance letters.
  • No financial data, guidance references, or presentation summaries were disclosed in this announcement.
  • The intimation includes a disclaimer that the schedule is subject to change due to exigencies on the part of the Investor, Analyst, or the Company.